Abstract
We recently described that the chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(β-Dribofuranosyl) quinoline-3-carboxylic acid (compound A) inhibits the human immunodeficiency virus type 1 (HIV-1) enzyme reverse transcriptase (RT), and its replication in primary cells. Based on these findings, we performed kinetic studies to investigate the mode of inhibition of compound A and its aglycan analog (compound B). We found that both molecules inhibited RT activity independently of the template/primer used. Nevertheless, compound A was 10-fold more potent than compound B. Compound A inhibited the RNA-dependent DNA polymerase (RDDP) activity of RT with an uncompetitive and a noncompetitive mode of action with respect to dTTP incorporation and to template/primer (TP) uptake, respectively. The kinetic pattern of the inhibition displayed by compound A was probably due to its greater affinity for the ternary complex (RT-TP-dNTP) than the enzyme alone or the binary complex (RT-TP). Besides, by means of molecular modeling, we show that compound A bound on the NNRTI binding pocket of RT. However, our molecule targets such a site by making novel interactions with the enzyme RT, when compared to NNRTIs. These include a hydrogen bridge between the 2-OH of our compound and the Tyr675 of the enzyme RTs chain B. Therefore, compound A is able to synergize with both a NRTI (AZT-TP) and a NNRTI (efavirenz). Taken together, our results suggest that compound A displays a novel mechanism of action, which may be different from classical NRTIs and NNRTIs.
Keywords: AIDS, HIV-1, Reverse transcriptase, Chloroxoquinolinic acid
Current HIV Research
Title: Characterization of HIV-1 Enzyme Reverse Transcriptase Inhibition by the Compound 6-Chloro-1,4-Dihydro-4-Oxo-1-(β-D-Ribofuranosyl) Quinoline-3-Carboxylic Acid Through Kinetic and In Silico Studies
Volume: 7 Issue: 3
Author(s): Thiago Moreno L. Souza, Diego Q. Rodrigues, Vitor F. Ferreira, Isakelly Pereira Marques, Fernanda da Costa Santos, Anna Claudia Cunha, Maria Cecilia Bastos Vieira de Souza, Izabel Christina de Palmer Paixao Frugulhetti, Dumith Chequer Bou-Habib and Carlos Frederico Leite Fontes
Affiliation:
Keywords: AIDS, HIV-1, Reverse transcriptase, Chloroxoquinolinic acid
Abstract: We recently described that the chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(β-Dribofuranosyl) quinoline-3-carboxylic acid (compound A) inhibits the human immunodeficiency virus type 1 (HIV-1) enzyme reverse transcriptase (RT), and its replication in primary cells. Based on these findings, we performed kinetic studies to investigate the mode of inhibition of compound A and its aglycan analog (compound B). We found that both molecules inhibited RT activity independently of the template/primer used. Nevertheless, compound A was 10-fold more potent than compound B. Compound A inhibited the RNA-dependent DNA polymerase (RDDP) activity of RT with an uncompetitive and a noncompetitive mode of action with respect to dTTP incorporation and to template/primer (TP) uptake, respectively. The kinetic pattern of the inhibition displayed by compound A was probably due to its greater affinity for the ternary complex (RT-TP-dNTP) than the enzyme alone or the binary complex (RT-TP). Besides, by means of molecular modeling, we show that compound A bound on the NNRTI binding pocket of RT. However, our molecule targets such a site by making novel interactions with the enzyme RT, when compared to NNRTIs. These include a hydrogen bridge between the 2-OH of our compound and the Tyr675 of the enzyme RTs chain B. Therefore, compound A is able to synergize with both a NRTI (AZT-TP) and a NNRTI (efavirenz). Taken together, our results suggest that compound A displays a novel mechanism of action, which may be different from classical NRTIs and NNRTIs.
Export Options
About this article
Cite this article as:
Souza L. Thiago Moreno, Rodrigues Q. Diego, Ferreira F. Vitor, Marques Pereira Isakelly, Santos da Costa Fernanda, Cunha Claudia Anna, de Souza Bastos Vieira Maria Cecilia, Paixao Frugulhetti de Palmer Izabel Christina, Bou-Habib Chequer Dumith and Fontes Frederico Leite Carlos, Characterization of HIV-1 Enzyme Reverse Transcriptase Inhibition by the Compound 6-Chloro-1,4-Dihydro-4-Oxo-1-(β-D-Ribofuranosyl) Quinoline-3-Carboxylic Acid Through Kinetic and In Silico Studies, Current HIV Research 2009; 7 (3) . https://dx.doi.org/10.2174/157016209788347958
DOI https://dx.doi.org/10.2174/157016209788347958 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Strategies and Agents to Lower Cardiovascular Risk by Increasing High Density Lipoprotein Cholesterol Levels
Current Medicinal Chemistry Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies
Current Pharmaceutical Design <i>In Silico</i> Modeling of COVID-19 Pandemic Course Differentiation Using the FOD Model
Coronaviruses Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology CoMSIA/QSAR Models for Vacuolar (H+) ATPase Inhibition by Selected Benzoate and Benzolactone Species
Letters in Drug Design & Discovery N-(Sulfamoylbenzoyl)-L-proline Derivatives as Potential Non-β-lactam ESBL Inhibitors: Structure-Based Lead Identification, Medicinal Chemistry and Synergistic Antibacterial Activities
Medicinal Chemistry Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases
Current Pharmaceutical Design The Antibacterial Activity of Isatin Hybrids
Current Topics in Medicinal Chemistry Anti-Allergic Effects of Quercetin and Quercetin Liposomes in RBL-2H3 Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Chemical Biology: Past, Present and Future
Current Chemical Biology Synthesis, Plasmodium falciparum Inhibitory Activity, Cytotoxicity and Solubility of N2 ,N4 -Disubstituted Quinazoline-2,4-diamines.
Medicinal Chemistry The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Natural Products in Mitigation of SARS CoV Infections
Current Medicinal Chemistry subject Index To Volume 2
Current Medicinal Chemistry - Central Nervous System Agents The Role of Atrial Fibrosis Detected by Delayed - Enhancement MRI in Atrial Fibrillation Ablation
Current Medical Imaging The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Chemometric Modeling of 5-Phenylthiophenecarboxylic Acid Derivatives as Anti-Rheumatic Agents
Current Computer-Aided Drug Design Agonists and Antagonists of Protease Activated Receptors (PARs)
Current Medicinal Chemistry Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets